The global DNA and gene cloning services market was valued at USD 2.51 billion in 2023 and is projected to grow at a CAGR of 15.43% from 2024 to 2030. Advancements in DNA and gene cloning technology, rising acceptance of gene therapy, and increasing demand for personalized medicine are some of the factors driving market growth.
Gene cloning enables researchers to investigate individual gene functions, replicate them, and isolate them by enzymatically cleaving DNA into fragments. This has resulted in significant advancements in genetic engineering and cloning. The rising number of infectious diseases elevates the need for discovering new vaccines. Recombinant vaccines can be designed using gene cloning to express specific antigens, allowing for more targeted immune responses and potentially reducing side effects.
DNA cloning enables the creation of libraries of cloned genes or gene fragments that can be used to screen for compounds that bind to or modulate the activity of the encoded proteins, leading to new drug discovery and development.
The ability to create multiple copies of specific genes through gene cloning has significantly contributed to personalized medicine. Gene cloning enables large-scale production of specific genes associated with diseases, allowing for more accurate and affordable genetic testing. Identifying genetic variations helps predict disease risk and assess an individual’s predisposition to certain conditions. Moreover, gene cloning plays a critical role in gene therapy by enabling the production of healthy copies of defective or missing genes causing diseases. These healthy copies are introduced into patients' cells using viral vectors to replace or compensate for the defective ones, thereby restoring normal function and alleviating disease symptoms.
Furthermore, recombinant proteins are artificially engineered proteins created by combining genetic material through biotechnological techniques, such as molecular cloning and gene editing. Recombinant proteins play a significant role in various industries by significantly enhancing efficiency and cost-effectiveness in various processes. For instance, enzymes modified through recombinant DNA technology are used in the food and beverage industry. In addition, they can be included in the animal feed in the breeding industry to increase nutritional value. In agriculture, recombinant proteins are used to develop genetically modified crops with enhanced traits and improved nutritional content.
The COVID-19 pandemic significantly impacted the DNA and gene cloning services market. The pandemic led to disruptions in supply chains, temporary closures of research facilities, and a shift in priorities towards combating the virus. However, the pandemic highlighted the importance of advanced genetic technologies in understanding and combating infectious diseases. The rapid development of vaccines using mRNA technology showcased the potential of genetic engineering in responding to public health emergencies.
The DNA and gene cloning services market is experiencing a significant degree of innovation driven by advancements in genetic engineering and cloning technologies and the increasing demand for personalized medicine and gene therapies. The market is witnessing a surge in the adoption of novel and advanced DNA cloning technologies, propelling growth and creating new opportunities for companies offering gene synthesis, custom cloning, sub-cloning, and other related services.
The industry is experiencing by a moderate level of merger and acquisition activities undertaken by several key players. This is due to several factors, including the desire to gain a competitive advantage in the industry and the need to consolidate in a rapidly growing market. However, market players are engaged in collaboration and partnerships to expand their service portfolios owing to the rapid advancements in the molecular & recombinant DNA technologies.
Gene cloning raises ethical concerns related to genetic manipulation, potential misuse of technology, and implications for biodiversity. Regulatory bodies often impose guidelines to ensure the responsible use of gene cloning techniques and to address ethical dilemmas associated with altering genetic material.
Key players are adopting the strategy of increasing production capacity and expanding their market reach to improve the availability of their products in diverse geographic areas. Additionally, companies are launching new platforms to strengthen their product & service portfolio. For example, in June 2024, Syngene International Ltd. launched a platform that uses high throughput clone screening for rapid and enhanced protein production.
The industry is witnessing moderate regional expansion, driven by an increasing customer base for cloned products. Furthermore, as scientific awareness of cell and gene therapy continues to grow globally and access to biotechnological tools improves in emerging markets, major market players are expected to enhance their regional expansion efforts.
The gene synthesis services segment dominated the market with the largest revenue share of 40.22% in 2023. Gene synthesis services play a crucial role in synthetic biology by enabling the creation of custom DNA sequences without the need for a template. This process allows researchers to design and construct genes with specific characteristics tailored to their research needs. Gene synthesis enables the optimization of gene expression levels through codon optimization. By designing genes with optimized codons, researchers can enhance protein production efficiency in various host cells. For instance, various companies provide gene synthesis services, including DNA synthesis, cloning, recombinant expression projects, and downstream services like sub-cloning, mutagenesis, and plasmid preparation.
Furthermore, the custom cloning services segment is expected to grow at the fastest CAGR of 16.49% from 2024 to 2030. Custom cloning services offer a range of benefits, including saving time, ensuring accuracy in cloning procedures, and providing access to specialized vectors and cloning techniques that may not be readily available in a laboratory setting. The custom cloning services include gene synthesis & mutagenesis services, molecular cloning services, shRNA & RNAi cloning services.
The DNA sequencing segment dominated the market with the largest revenue share of 39.51% in 2023 and is expected to grow at the fastest CAGR during the forecast period. Gene cloning plays a crucial role in DNA sequencing by allowing scientists to create copies of specific genes for further analysis. In DNA sequencing, gene cloning amplifies and isolates a particular gene of interest from an organism’s genome.
This process involves inserting the gene into a vector, such as a plasmid or a viral vector, which can then be introduced into host cells for replication. The replicated gene can be sequenced using various techniques to determine its nucleotide sequence accurately. Thus, once the cloned gene is isolated and confirmed, it can be subjected to DNA sequencing techniques to determine its exact nucleotide sequence. This information is crucial for understanding the genetic makeup and function of the gene.
Moreover, the mutagenesis segment is expected to witness significant growth from 2024 to 2030. Gene cloning plays a crucial role in mutagenesis, allowing researchers to introduce specific mutations into genes for various studies and applications. By combining the techniques of gene cloning and mutagenesis, researchers can create customized genetic constructs for a wide range of applications in molecular biology, biotechnology, and genetics. The ability to clone genes and introduce precise mutations has revolutionized the field of genetic engineering and opened up new possibilities for studying gene function and regulation.
The academic and research institutes segment dominated the market with the largest revenue share of 38.41% in 2023. The research institutes are entering into collaborations with service providers to speed up their research programs that require the characterization and synthesis of gene fragments. For instance, in January 2024, GSK and Elegen Corporation entered into a collaboration to develop cell-free DNA-based vaccines and medicines. DNA and gene cloning services are crucial in bridging basic research with clinical applications in translational studies. Scientists use these services to develop potential therapies, diagnostic tools, or biomarkers for therapy development.
The CROs & CMOs segment is expected to grow at the fastest CAGR of 16.55% from 2024 to 2030. The presence of a high number of contract research organizations (CROs) providing gene synthesis services is expected to increase revenue in the region. For instance, GenScript has established a significant presence across the North American region. It offers a broad range of services, including antibody drug development and custom gene synthesis services.
North America DNA and gene cloning services market dominated and accounted for a 40.98% revenue share in 2023. This growth is attributed to the region’s advanced healthcare infrastructure, strong presence of leading biotechnology firms, and significant funding for recombinant DNA (rDNA) technology research. Furthermore, increasing demand for personalized medicine, and the rise in the prevalence of chronic & hereditary diseases are expected to boost the DNA and gene cloning services market.
The DNA and gene cloning services market in the U.S. is anticipated to grow from 2024 to 2030 due to increasing government funding & growing focus on targeted treatments, regenerative medicine and the rising prevalence of diseases. Moreover, increasing research in the fields of drug discovery and personalized medicine, with a strong presence of biotechnology and biopharmaceutical companies, is further anticipated to fuel market growth.
The Europe DNA and gene cloning services market is anticipated to grow over the forecast period owing to the strong presence of biopharmaceutical companies producing recombinant vaccines and biologics. Moreover, increasing research and development activities, collaborations between pharmaceutical companies and research institutions, and a growing demand for novel antibiotics, enzymes, etc., further propels market growth.
The DNA and gene cloning services market in the UK is expected to grow at CAGR of 17.2%over the forecast period due to rising prevalence of cancer and growing demand for targeted therapies. Furthermore, government laws regarding genetically modified crops are likely to boost the DNA and gene cloning services market. For instance, in March 2023, the Government of England legalized the commercial production of gene-edited food. Thus, using rDNA technology, scientists can enhance agricultural outcomes & food production.
Germany DNA and gene cloning services market is anticipated to experience growth from 2024 to 2030, driven by the increasing incidence of genetic disorders and the support of government policies for research in regenerative medicine and personalized therapeutics.
The DNA and gene cloning services market in France is expected to grow over the forecast period due to the growing investments in research and development, advancements in biotechnology, and a growing emphasis on precision medicine approaches for cancer treatment.
The Asia Pacific DNA and gene cloning services marketis expected to experience rapid growth, with a projected CAGR of 16.76% from 2024 to 2030. This is attributed to the rising prevalence of chronic diseases, increasing research activities, advancements in genetic engineering, rising adoption of gene therapies, and a strong presence of biotechnology and biopharmaceutical companies in the region.
The DNA and gene cloning services market in China is anticipated to grow over the forecast period due to increasing investments in healthcare innovation and research. The country’s focus on advancing biotechnology and immunotherapy coupled with the rising awareness of personalized medicine, is driving the expansion of the DNA and gene cloning services market in China.
The Japan DNA and gene cloning services marketis expected to witness rapid growth over the forecast period. The increasing prevalence of diseases, coupled with the growing oncology research, anticipates market growth.
The DNA and gene cloning services market in India is anticipated to grow over the forecast period due to the rising prevalence of cancer in the country. In addition, increasing government funding for cancer research and the presence of biopharmaceutical companies involved in vaccine development further boosts market growth.
The Middle East and Africa DNA and gene cloning services marketis poised to grow in the near future. Increasing applications of biotechnology and immunomedicine, along with growing applications of biotechnology in agriculture, are contributing to its expansion.
The DNA and gene cloning services market in Saudi Arabia is expected to grow over the forecast period due to increasing investments in healthcare innovation and research. The country’s focus on advancing biotechnology and genomics, coupled with the rising awareness of genetic drugs and personalized medicine, is driving the expansion of the market.
The Kuwait DNA and gene cloning services market is anticipated to witness growth over the forecast period owing to the escalating investment in scientific research and development by both governmental and private entities. This investment is propelling advancements in oncology research, consequently presenting opportunities for developing novel and enhanced cancer therapies.
Key players operating in the market are undertaking various initiatives to strengthen their market presence and increase the reach of their products and services. Strategies such as expansion activities and partnerships are playing a key role in propelling the market growth.
The following are the leading companies in the DNA and gene cloning services market. These companies collectively hold the largest market share and dictate industry trends.
In June 2024, GenScript Biotech Corporation launched the FLASH gene synthesis service. This system reduces the sequence-to-plasmid construct time facilitating R&D in antibody drugs, vaccines, and cell & gene therapy.
In November 2023, Twist Bioscience launched Twist Express Genes to deliver clonal genes and gene fragments at scale and with rapid turnaround times.
In August 2020, Telesis Bio launched BioXp 3250 system for synthetic biology workflow. This platform aims to accelerate the development of new biologics and vaccines. It allows researchers to generate large DNA fragments of up to 7kb at high speed without compromising accuracy. These factors would further contribute to the segment’s growth.
Report Attribute |
Details |
Market size value in 2024 |
USD 2.88 billion |
Revenue forecast in 2030 |
USD 6.82 billion |
Growth rate |
CAGR of 15.43% from 2024 to 2030 |
Actual data |
2018 - 2023 |
Forecast period |
2024 - 2030 |
Quantitative units |
Revenue in USD million/billion and CAGR from 2024 to 2030 |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Service, application, end use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Mexico; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Argentina; South Africa; Saudi Arabia; UAE; Kuwait |
Key companies profiled |
Bio-Techne; Charles River Laboratories; Eurofins Scientific; GenScript; Danaher Corporation; Syngene International Limited; Twist Bioscience; Thermo Fisher Scientific Inc.; Merck KGaA; Curia Global, Inc. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global DNA and gene cloning services market report based on service, application, End use, and region.
Service Outlook (Revenue, USD Million, 2018 - 2030)
Gene Synthesis
Custom Cloning
Sub-cloning
Others
Application Outlook (Revenue, USD Million, 2018 - 2030)
DNA Sequencing
Mutagenesis
Genotyping
Others
End use Outlook (Revenue, USD Million, 2018 - 2030)
Academic & Research Institutes
Pharmaceutical & Biotechnology Companies
CMOs & CROs
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Mexico
Europe
Germany
UK
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
China
Japan
India
South Korea
Australia
Thailand
Latin America
Brazil
Argentina
MEA
South Africa
Saudi Arabia
UAE
Kuwait
b. The global DNA and gene cloning services market size was estimated at USD 2.51 billion in 2023 and is expected to reach USD 2.88 billion in 2024.
b. The global DNA and gene cloning services market is expected to grow at a compound annual growth rate of 15.43% from 2024 to 2030 to reach USD 6.82 billion by 2030.
b. North America dominated the DNA and gene cloning services market with a share of 40.98% in 2023. This is attributable to the rising adoption of cloning techniques for the development of novel therapeutics for chronic diseases.
b. Some key players operating in the DNA and gene cloning services market include Bio-Techne; Charles River Laboratories; Eurofins Scientific; GenScript; Danaher Corporation; Syngene International Limited; Twist Bioscience; Thermo Fisher Scientific Inc.; Merck KGaA; Curia Global, Inc.
b. Key factors that are driving the market growth include advancements in DNA and gene cloning technology, rising acceptance of gene therapy, and increasing demand for personalized medicine.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."